ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Exclusive license agreement with ALK-Abelló to commercialize neffy ® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties Well-capitalized with $349.
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists ...
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class (i) targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended September 30,
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results
Expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024 Solid financial position enables Vaxart to attain multiple regulatory and clinical milestones Conference call today at 4:30 p.
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Building on its collaboration with Enable Injections, Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the combination of Serina’s lead candidate, SER-252 (POZ-apomorphine),
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
Revenue Increased 17% Quarter over QuarterOperating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ETLITTLETON, Colo., ...
Hosted on MSN11mon
Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance
Vivos Therapeutics Inc. shares jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea. The U.S ...
Yahoo Finance3d
Vivos Therapeutics, Inc. (VVOS)
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and ChildrenLITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE ...
Proactiveinvestors UK10mon
Vivos Therapeutics leads the way with noninvasive solutions for sleep issues
Effective January 1, 2025, these codes will streamline insurance coverage and reimbursement for Vivos’ devices, designed to treat obstructive sleep apnea (OSA) in both adults and children.
Study links obstructive sleep apnea to increased dementia risk in women
A common yet underdiagnosed sleep disorder contributes to the development of dementia among adults -; particularly women, a ...
Stockhouse1mon
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
New Medical Codes will Facilitate Billing by Commercial Payers for Vivos CARE Treatment for Obstructive Sleep Apnea in Adults and Children LITTLETON, Colo., Oct. 08, 2024 (GLOBE NEWSWIRE) -- ...
WebMD2y
Sleep Apnea Resource Center
Obstructive sleep apnea – disruptive snoring – is linked to conditions such as high blood pressure and heart disease and other hazards to your health. Learn more from WebMD. Pillows that put ...
Tom's Guide1mon
Think you have sleep apnea? Experts share the 5 main symptoms and what to do
Sleep apnea is a condition where your breathing stops and starts while you're sleeping, and it affects over 936 million people worldwide. Because sleep apnea is so common, it's likely that you ...